REG-The Vanguard Group, Inc. Form 8.3 - The Vanguard Group, Inc.: Sanofi

Sanofi SAAnnouncement

01/12/2022 15:15

============

   The Vanguard Group, Inc. ( IRSH)
   Form 8.3 - The Vanguard Group, Inc.: Sanofi

   01-Dec-2022 / 15:09 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ═══════════════════════════════════════════════════════════════════════════

                                                                          Ap19

                                                                              

                                                                      FORM 8.3

                                                                              

                              IRISH TAKEOVER PANEL

                                         

    DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
                                   RULES, 2013

                                         

    DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING
                                   1% OR MORE

                                         

                               1.  KEY INFORMATION

    

   ┌────────────────────────────────────────────────┬────────────────────────┐
   │Name of person dealing (Note 1)                 │The Vanguard Group, Inc.│
   ├────────────────────────────────────────────────┼────────────────────────┤
   │Company dealt in                                │Sanofi                  │
   ├────────────────────────────────────────────────┼────────────────────────┤
   │Class of relevant security to which the dealings│Ordinary Shares         │
   │being disclosed relate (Note 2)                 │                        │
   ├────────────────────────────────────────────────┼────────────────────────┤
   │Date of dealing                                 │29 November 2022        │
   └────────────────────────────────────────────────┴────────────────────────┘

    

   2.  INTERESTS AND SHORT POSITIONS

    

   (a)  Interests and short positions (following dealing) in the class of
   relevant security dealt in (Note 3)

   ┌───────────────────────────────────────────┬────────────────┬───────────┐
   │                                           │      Long      │   Short   │
   ├───────────────────────────────────────────┼──────────┬─────┼───────┬───┤
   │                                           │Numbers   │(%)  │Numbers│(%)│
   ├───────────────────────────────────────────┼──────────┼─────┼───────┼───┤
   │(1) Relevant securities                    │41,259,671│3.26%│       │   │
   ├───────────────────────────────────────────┼──────────┴─────┼───────┴───┤
   │(2) Derivatives (other than options)       │                │           │
   ├───────────────────────────────────────────┼────────────────┼───────────┤
   │(3) Options and agreements to purchase/sell│                │           │
   ├───────────────────────────────────────────┼──────────┬─────┼───────┬───┤
   │Total                                      │41,259,671│3.26%│       │   │
   └───────────────────────────────────────────┴──────────┴─────┴───────┴───┘

    

   (b)  Interests and short positions in relevant securities of the company,
   other than the class dealt in (Note 3)

   ┌───────────────────────────────────────────┬───────────┬───────────┐
   │Class of relevant security:                │   Long    │   Short   │
   ├───────────────────────────────────────────┼───────┬───┼───────┬───┤
   │                                           │Numbers│(%)│Numbers│(%)│
   ├───────────────────────────────────────────┼───────┼───┼───────┼───┤
   │(1) Relevant securities                    │       │   │       │   │
   ├───────────────────────────────────────────┼───────┴───┼───────┴───┤
   │(2) Derivatives (other than options)       │           │           │
   ├───────────────────────────────────────────┼───────────┼───────────┤
   │(3) Options and agreements to purchase/sell│           │           │
   ├───────────────────────────────────────────┼───────┬───┼───────┬───┤
   │Total                                      │       │   │       │   │
   └───────────────────────────────────────────┴───────┴───┴───────┴───┘

    

   Ap20

    

   1.  Dealings (Note 4)

    

   (a)  Purchases and sales

   ┌─────────────┬─────────────────────────────┬───────────────────────┐
   │Purchase/sale│Number of relevant securities│Price per unit (Note 5)│
   ├─────────────┼─────────────────────────────┼───────────────────────┤
   │             │                             │                       │
   └─────────────┴─────────────────────────────┴───────────────────────┘

    

    

   (b)  Derivatives transactions (other than options transactions)

   ┌──────────────┬─────────────────────┬──────────────────────────┬─────────┐
   │Product name, │Nature of transaction│Number of relevant        │Price per│
   │              │                     │securities                │unit     │
   │e.g. CFD      │(Note 6)             │                          │         │
   │              │                     │(Note 7)                  │(Note 5) │
   ├──────────────┼─────────────────────┼──────────────────────────┼─────────┤
   │Not Applicable│                     │                          │         │
   └──────────────┴─────────────────────┴──────────────────────────┴─────────┘

    

    

   (c)  Options transactions in respect of existing relevant securities

    

   (i)  Writing, selling, purchasing or varying

    

   ┌──────────┬───────────┬──────────┬────────┬─────────┬──────┬─────────────┐
   │Product   │Writing,   │Number of │        │Type,    │      │             │
   │name,     │selling,   │securities│        │e.g.     │      │Option money │
   │          │purchasing,│to which  │Exercise│American,│Expiry│paid/received│
   │e.g. call │varying    │the option│price   │European │date  │per unit     │
   │option    │etc.       │relates   │        │etc.     │      │(Note 5)     │
   │          │           │(Note 7)  │        │         │      │             │
   ├──────────┼───────────┼──────────┼────────┼─────────┼──────┼─────────────┤
   │Not       │           │          │        │         │      │             │
   │Applicable│           │          │        │         │      │             │
   └──────────┴───────────┴──────────┴────────┴─────────┴──────┴─────────────┘

    

    

   (ii)  Exercising

    

   ┌────────────────┬────────────────────┬────────────────────────────────┐
   │Product name,   │                    │Exercise price per unit (Note 5)│
   │                │Number of securities│                                │
   │e.g. call option│                    │                                │
   ├────────────────┼────────────────────┼────────────────────────────────┤
   │Not Applicable  │                    │                                │
   └────────────────┴────────────────────┴────────────────────────────────┘

    

    

   (e)  Other dealings (including transactions in respect of new securities)
   (Note 4)

   ┌─────────────────────┬───────┬────────────────────────┐
   │Nature of transaction│       │Price per unit          │
   │                     │Details│                        │
   │(Note 8)             │       │(if applicable) (Note 5)│
   ├─────────────────────┼───────┼────────────────────────┤
   │Not Applicable       │       │                        │
   └─────────────────────┴───────┴────────────────────────┘

                                                                          Ap21

    

   2.  OTHER INFORMATION

    

   Agreements, arrangements or understandings relating to options or
   derivatives

    

    

   ┌─────────────────────────────────────────────────────────────────────────┐
   │Full details of any agreement, arrangement or understanding between the  │
   │person disclosing and any other person relating to the voting rights of  │
   │any relevant securities under any option referred to on this form or     │
   │relating to the voting rights or future acquisition or disposal of any   │
   │relevant securities to which any derivative referred to on this form is  │
   │referenced. If none, this should be stated.                              │
   ├─────────────────────────────────────────────────────────────────────────┤
   │                                                                         │
   │                                                                         │
   │                                                                         │
   │                                                                         │
   │                                                                         │
   │                                                                         │
   │                                                                         │
   └─────────────────────────────────────────────────────────────────────────┘

    

    

    

    

   Is a Supplemental Form 8 attached? (Note 9)                           NO

    

   ┌────────────────────────────────────────────────────────┬────────────────┐
   │Date of disclosure                                      │01 December 2022│
   ├────────────────────────────────────────────────────────┼────────────────┤
   │Contact name                                            │Shawn Acker     │
   ├────────────────────────────────────────────────────────┼────────────────┤
   │Telephone number                                        │001-610-669-8989│
   ├────────────────────────────────────────────────────────┼────────────────┤
   │If a connected EFM, name of offeree/offeror with which  │                │
   │connected                                               │                │
   ├────────────────────────────────────────────────────────┼────────────────┤
   │If a connected EFM, state nature of connection (Note 10)│                │
   └────────────────────────────────────────────────────────┴────────────────┘

    

    

   ═══════════════════════════════════════════════════════════════════════════

   Category Code: RET - Sanofi
   TIDM:          IRSH
   LEI Code:      5493002789CX3L0CJP65
   Sequence No.:  205631
   EQS News ID:   1503367


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    1 fncls.ssp?fn=show_t_gif&application_id=1503367&application_name=news&site_id=refinitiv

References

   Visible links


============